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a b s t r a c t
Silicosis is the most frequent pneumoconiosis, resulting from the inhalation of mineral 
dust containing silica or silicates. It is mainly characterized by irreversible lung fi brosis, 
being associated with the development of other diseases, such as pulmonary tubercu-
losis, lung cancer and autoimmune conditions. The connective tissue disease following 
exposure to silica occurs usually 15 years after the initial exposure. Erasmus syndrome 
consists of the association of systemic sclerosis following exposure to silica with or with-
out silicosis. We report the cases of two patients diagnosed with silicosis, who developed 
systemic sclerosis.
© 2013 Elsevier Editora Ltda. All rights reserved.
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r e s u m o
A silicose é a pneumoconiose mais frequente, decorrente da inalação de sílica ou de poeiras 
minerais contendo silicatos, caracterizada principalmente pela fi brose pulmonar de caráter 
irreversível. Está associada com o desenvolvimento de outras doenças, incluindo tubercu-
lose pulmonar, câncer pulmonar e doenças autoimunes. A doença do tecido conjuntivo 
posterior à exposição à sílica ocorre geralmente após 15 anos do início da exposição. A 
síndrome de Erasmus refere-se ao desenvolvimento de esclerose sistêmica em indivíduos 
previamente expostos à sílica e que apresentavam ou não silicose. Os autores relatam dois 
casos de pacientes com diagnóstico de silicose que desenvolveram esclerose sistêmica.
© 2013 Elsevier Editora Ltda. Todos os direitos reservados.
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Introduction
Pneumoconiosis is a group of lung diseases associated with 
exposure to dust particles, such as, silica, cobalt and talc. The 
disease is usually related to occupational exposure.1 Inhala-
tion of silica dust associates with the occurrence of silicosis, 
chronic obstructive pulmonary disease, lung cancer, and re-
nal failure, and the increased risk for pulmonary tuberculosis 
and autoimmune diseases, such as systemic sclerosis (SSc), 
rheumatoid arthritis and systemic lupus erythematosus.1,2 
Systemic sclerosis is an autoimmune disease with vas-
cular changes and diffuse tissue fi brosis. The association of 
previous exposure to silica and SSc was described by Erasmus 
in 1957.2,3
This study reports two cases of Erasmus syndrome in pa-
tients with history of occupational exposure to silica, who, 
ten years after being diagnosed with pneumoconiosis, devel-
oped SSc. The fi rst patient had skin manifestations character-
istic of diffuse SSc, while the second had limited SSc (CREST 
syndrome). 
Case 1 
The patient is a 35-year-old male with an occupational his-
tory of quartz crushing from 1996 to 2001. He was released 
from work because of dyspnea on exertion. He sought a pul-
monologist, who, after clinical assessment and complemen-
tary tests, made a presumptive diagnosis of pneumoconiosis, 
due to the presence of 95% free silica in the sand resulting 
from crushing. 
Lung biopsy was performed and the histopathology evi-
denced mononuclear infl ammatory infi ltrate with frequent 
areas of fi brosis, suggesting bronchiolitis obliterans with orga-
nizing pneumonia (BOOP). Once established the diagnosis of 
subacute silicosis, pulse therapy was initiated with methyl-
prednisolone (1 g) for three days, and maintenance with pred-
nisone. The symptoms subsided. 
Ten years after the diagnosis of pneumoconiosis, the pa-
tient was admitted to the Rheumatology Service of the Hospi-
tal Universitário Getúlio Vargas (HUGV), in the city of Manaus, 
Amazonas state, reporting dyspnea on mild exertion, dyspha-
gia to solids, postprandial vomiting, digital ulcers, and 5-kg 
weight loss in 30 days. He reported neither smoking nor illegal 
drug use. 
On physical examination, the patient was emaciated, 
showing scleroderma facies, sclerodactyly, diffuse skin thick-
ening with modifi ed Rodnan score of 30, facial telangiectasia, 
leukomelanoderma, Raynaud’s phenomenon, distal phalan-
geal resorption, digital micro-scars, ulcerated lesions on his 
right medial malleolus and elbows. Pulmonary auscultation: 
reduced respiratory sounds in the bases. Cardiac ausculta-
tion: regular heart rhythm with P2 > A2, and blood pressure 
of 160/90 mm Hg. The laboratory tests were as follows: he-
moglobin, 10.9 g/dL; hematocrit, 35%; leukocyte count: 9700/
mm3; erythrocyte sedimentation rate (ESR), 20 mm; negative 
C-reactive protein; antinuclear antibody (ANA) HEp-2, 1:1280, 
nuclear speckled pattern; negative anti-Scl 70 antibody and 
rheumatoid factor. Negative serology for HIV, HBV and HCV. 
Negative tuberculin skin test. Normal urinalysis. Spirometry: 
moderate restrictive ventilatory disorder. Chest computed 
tomography (CT): ground glass opacities (Fig. 1). Echocardio-
gram: left ventricular ejection fraction of 63% and pulmonary 
artery systolic pressure of 53 mm Hg. The diagnosis of diffuse 
SSc was established on clinical basis. Prednisone (40 mg/day), 
amlodipine (10 mg/day) and cyclophosphamide (1 g/month) 
were initiated. The patient’s clinical fi ndings improved.
Case 2
The patient was a 38-year-old male, miner, who worked with 
explosives without observing occupational safety and health 
regulations. He initiated parenchymatous lung disease ten 
years before seeking medical help. 
His chest CT showed pleural pneumopathy mainly in the 
upper lobes, left pleural effusion and mediastinal lymphad-
enomegaly. Lung biopsy showed macrophage infi ltrate, pul-
monary fi brosis and silica particles in the tissue (polaroid 
materials at 90º). The pleural effusion culture was positive for 
tubercle bacilli. Treatment with tuberculostatic drugs for six 
months was initiated. 
The patient was referred to the Rheumatology Service of 
the HUGV, reporting skin thickening in the face, forearms and 
hands for one year, associated with distal dysphagia to solids 
and dyspnea on exertion. One month before, as his symptoms 
got worse, he was hospitalized with dyspnea on mild exer-
tion, epigastralgia with worsening of dysphagia, fatigue and 
ulcers in his hands. He reported neither smoking nor alcohol-
ism. 
His physical examination showed microstomia, sclerodac-
tyly, modifi ed Rodnan score of 14, leukomelanoderma, Rayn-
aud’s phenomenon, digital resorption, disseminated skin 
ulcers (Fig. 2), polyarthritis of his proximal interphalangeal 
joints, wrists, elbows, knees and ankles. Cardiac ausculta-
tion showed regular cardiac rhythm with P2 > A2. Pulmonary 
Fig. 2 – Sclerodactyly and ulcers on extensor surfaces.
Fig. 1 – Reticulonodular infi ltrate, ground glass opacities, 
some of confl uent aspect, disseminated throughout the 
parenchyma in both lungs, and bronchiectasis in the 
lower lobes.
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auscultation: respiratory sounds with crepitant rales in the 
bases. Laboratory fi ndings: hemoglobin, 8.9 g/dL; hematocrit, 
32%, leukocyte count: 14700/mm3; ESR: 34 mm; negative se-
rology for HIV, cytomegalovirus, and toxoplasmosis; rubella 
IgM, negative, and IgG, positive; negative culture and search 
for tubercle bacilli in the sputum. Tuberculin skin test: 3 mm. 
Anti-Scl 70 and anti-DNA antibodies, negative, and ANA HEp-
2, 1:5120, nucleolar pattern. Echocardiography: severe pulmo-
nary hypertension and right overload. Spirometry: restrictive 
ventilatory disorder. Chest CT: sequela of the specifi c infl am-
matory process in the upper lobes, subpleural and intraparen-
chymatous nodular images, cystic bronchial dilations, some 
of which were confl uent, with a honeycombing aspect, and 
bilateral pleural thickening. The diagnosis of limited SSc was 
established, and the following drugs were initiated: nifedip-
ine retard (20 mg, 12/12 h); omeprazole (40 mg/day); metoclo-
pramide and oxacillin (1.5 g, 6/6 h). Severe sepsis from a skin 
focus developed. The antibiotic spectrum was widened and 
intensive care support initiated, but the patient died. 
Discussion
Silicosis is a pneumoconiosis caused by inhalation of free 
silica. It is associated with abnormalities of the humoral and 
cellular immunity, and positivity for antinuclear antibody and 
rheumatoid factor, hypergammaglobulinemia and alterations 
in T-helper and T-suppressor lymphocytes.3,4 
Silicosis is divided into three clinical presentation forms: 
acute, accelerated, and chronic. The acute form occurs 
months after an intense exposure to silica particles, fi nely 
divided and newly broken, as in sand crushing and rock per-
foration. The accelerated form occurs 5-10 years after expo-
sure to silica particles. The chronic form is the most common 
presentation of silicosis, occurring usually 10-15 years after 
exposure or latency.1 
Systemic sclerosis is a chronic infl ammatory, autoimmune 
disease characterized by the excessive production of colla-
gen, which causes tissue fi brosis, small vessel impairment 
and specifi c autoimmune response.5-7 There is evidence of the 
association of SSc with occupational and environmental fac-
tors. In 1957, Erasmus reported cases of SSc in gold miners in 
South Africa, who had been exposed to silica powder.8-10
The mechanism of the association of exposure to silica 
and SSc seems to involve the infl ammatory response trig-
gered by silica after phagocytosis and release of mediators 
by activated alveolar macrophages.9 Initially, silica particles 
induce, through either their direct contact with water and 
lipoproteins of the bronchioloalveolar lining or activation of 
the macrophages and epithelial cells, the formation of free 
radicals. When the production of such radicals exceeds the 
antioxidant defense mechanisms, the following might hap-
pen: damage of type I pneumocytes; increased activation of 
macrophages; induction and proliferation of type II pneumo-
cytes. When proteolytic enzymes are released, more reactive 
species of oxygen and nitrogen build up, in addition to the 
release of infl ammatory cytokines, such as tumor necrosis 
factor alpha, transforming growth factor β, interleukin 1, and 
interleukin 6. Those cytokines recruit macrophages, neutro-
phils and lymphocytes, causing alveolitis and consequent 
epithelial barrier integrity loss, thus allowing the entrance 
of silica particles into the interstitium. The net result is the 
overproliferation of fi broblasts and collagen production, with 
consequent interstitial fi brosis.1,4,5,7,9
The connective tissue disease occurs, on average, 15 
years after exposure to silica, with image patterns of linear 
ground glass opacities, honeycombing and small subpleural 
nodules; such changes cannot be distinguished from idio-
pathic SSc.10,11
A meta-analysis has suggested that exposure to silica is 
associated with an increase in the incidence of SSc, espe-
cially in the male sex, but further studies are required.12,13 
The anti-Scl 70 antibody relates to skin and peripheral 
vascular involvement, and pulmonary interstitial fi brosis. The 
patients here reported, both negative for the anti-Scl 70 anti-
body, showed a restrictive pulmonary pattern, which can be 
present in both SSc and silicosis. Rustin et al.13 have reported 
17 patients with SSc associated with silica, of whom, 14 had 
limited SSc and 3 had diffuse SSc. All patients had Raynaud’s 
phenomenon, while pulmonary interstitial fi brosis occurred 
in 16 patients, 8 of whom were positive for the anti-Scl 70 
antibody. 
Briefl y, pneumoconiosis due to exposure to silica can 
evolve to SSc. It is worth noting that occupational exposure 
relates to an increase in the occurrence of severe diseases, 
and that primary prevention can be performed by using indi-
vidual protection devices for professionals exposed.
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